ImmunityBio converts from Immunomedics | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
ImmunityBio converts from Immunomedics

An SI Board Since February 2023

Posts	SubjectMarks	Bans	Symbol
1498	51	0	IBRX

Emcee: TinfoilHat	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1110	While they need to raise cash, this appears more dilution at below market rates.	Davidoff	1	7/25/2025
1109	now that they filed the 8-K, looks like they issued the shares at $2.70, with a	luckydog88	1	7/25/2025
1108	Both hitting the wires this morning: ImmunityBio Reports 60% Increase in Revenu	luckydog88	1	7/25/2025
1107	Couldn’t agree more!	jargonweary	-	7/24/2025
1106		Olecranon	-	7/24/2025
1105	Yes. Nice move on nice volume!	erippetoe	-	7/23/2025
1104	Up 10.9% on 8.8MM shares vs. Average volume of 6.4MM. I would like to think the	TripleE3	1	7/23/2025
1103	Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year	luckydog88	-	7/22/2025
1102	Anktiva is an expensive life extending treatment. There is only a certain class	waitwatchwander	1	7/16/2025
1101	To be clear, my post was not a comment one way or the other about the merits or	jargonweary	2	7/16/2025
1100	Yes fundamentally they have to perform. Revenue must increase exponentially and	sukit	2	7/15/2025
1099	It is painfully obvious that a strategy of photo ops with the president, flatter	jargonweary	6	7/15/2025
1098	Megan Kelly, not exactly my idea of a credible source for expanding the merits	galt	5	7/14/2025
1097	Latest interview of PSS by Megan Kelly x.com Summary by Grok: In the interview	End2War	3	7/11/2025
1096	UK approval pr: ir.immunitybio.com	zagnut1	1	7/7/2025
1095	New phase 1 study clinicaltrials.gov	mannamal	1	7/7/2025
1094	This is good news primarily because it isn’t bad news. By that I mean that appr	jargonweary	-	7/6/2025
1093	Maybe they wanted to get the biggest bang for their buck and put it out on Monda	zagnut1	-	7/6/2025
1092	nothing on yahoo news and nothing reported on my Schwab account news.........	urslor	-	7/6/2025
1091	Nice! Will be very interesting to see price action on Monday. In theory this sh	TinfoilHat	3	7/5/2025
1090	Well, we got some significant and good news yesterday - Anktiva approved in Gre	Fitzhughlaw	8	7/5/2025
1089	Hazard a guess, instability in policies, market, company financials and the thre	dorightbythem	1	6/17/2025
1088	I don't see any news either. I would not necessarily say it is down on low	luckydog88	-	6/17/2025
1087	Anyone have any insight on today’s drop? I don’t see any news unless it’s just a	zagnut1	-	6/17/2025
1086	Derivation of ImmunityBio's Car-NK strategy After AI research, a potential	Huggenberg	2	6/15/2025

Go to reply# or date (mm/dd/yy):